ERIKA ROBAUGH: Open Payments
NPI 1437525987 · CALIFORNIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$701 in 35 payments from 14 companies in 2025. Trend: 2023 $338 · 2024 $356 · 2025 $701
Food & beverage: $701
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $179 |
| GlaxoSmithKline, LLC. | 5 | $111 |
| Merck Sharp & Dohme LLC | 3 | $52 |
| Lilly USA, LLC | 3 | $47 |
| Pulmonx Corporation | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Exact Sciences Corporation | 2 | $42 |
| PFIZER INC. | 2 | $32 |
| Janssen Biotech, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
Products named: TRELEGY ELLIPTA, Wegovy, GARDASIL 9, Rybelsus, CHARTIS CATHETER, CAPLYTA, Cologuard Collection Kit, Ozempic.
Industry payments across PA — which companies pay providers there.
